It is becoming clear that postnatal neovascularization involves circulating endothelial progenitor cells (EPCs), which home to sites of neovascularization and differentiate into endothelial cells in a manner consistent with a process initially termed "vasculogenesis" (1) . These circulating EPCs derive from hematopoietic stem cells and contribute to reparative processes, including neovascularization after ischemia (2, 3) . Ischemia, vascular trauma, and proangiogenic chemokines stimulate EPC mobilization from the bone marrow (4 -6) . In particular, ischemia was shown to enhance circulating EPC levels by vascular endothelial growth factor (VEGF)-mediated mobilization of bone marrow-derived EPCs (5). Mobilized EPCs are then attracted to ischemic areas by locally elevated VEGF or stromal cell-derived factor-1 levels (7). The functional
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regeneration of ischemic tissue by improved neovascularization and possibly tissue repair is critically dependent on the mobilization and integration of EPCs into the ischemic tissue. Moreover, infusions of EPCs expanded ex vivo can limit scar extension in the ischemic myocardium (8) and improve the recovery of contractility and thereby may be useful as a novel therapeutic approach (9) . However, aging may constitute a potential limitation to the ability of progenitor cells to sustain ischemic tissue neovascularization and repair.
Aging is one of the major risk factors for coronary artery disease (CAD) and is associated with a reduction of the functional activity of the endothelium (10) . In an animal model, aging also appeared to impair neovascularization after ischemia (11) . Moreover, increasing age was shown to be associated with reduced levels of circulating EPCs in patients with CAD (12) , thereby providing first evidence of dysfunctional regulation of EPCs in elderly individuals. Age may interfere with neovascularization at various steps ( Fig. 1 ).
Although basal hematopoiesis is maintained in aging, the capacity of reacting to stress-induced mobilization gradually declines with increased age (for a review see [13] ). Thus, one may speculate that elderly patients may show a limited response toward EPC-mobilizing stimuli after critical ischemia.
Age may also interfere with the functional activity of stem/progenitor cells. Edelberg et al. (14) previously demonstrated that only transplantation of young bone marrowderived cells restored age-associated impaired neovascularization, whereas bone marrow of aged mice was not effective. Moreover, the migratory capacity of peripheral blood-derived EPCs of elderly patients with CAD is significantly reduced (12) . Finally, age may interfere with the survival of circulating stem/progenitor cells. An increased turnover rate in the progenitor cell population with increased susceptibility to apoptosis may be due to an imbalance in pro-and anti-apoptotic factors or a decline in the antioxidant defense, as suggested for the aging process in general.
In this issue of the Journal, Scheubel et al. (15) provide novel evidence that age leads to a reduction of VEGF, which might limit mobilization and survival/differentiation of EPCs. The authors report that the number of circulating CD34/CD133 cells, which defines a subpopulation of immature hematopoietic precursor cells, and VEGF levels are reduced as a function of age in 50 patients (age 43 to 80 years) before undergoing coronary artery bypass graft surgery (CABG). In this group of patients, the increase in VEGF and EPC levels after CABG was consistently depressed in older patients. This observation is supported by previous experimental studies demonstrating a reduction of VEGF levels during aging (16) . Interestingly, in the present study, other risk factors for CAD did not apparently explain the observed differences, although other studies showed an inverse correlation of CAD risk factors with EPC levels (12, 17) . Also, the plasma levels of several other cytokines and chemokines were not changed in this group of patients, suggesting that systemically depressed VEGF levels may play a crucial role in the reduction of EPC levels. However, due to limitations inherent in the clinical scenario, the causal role of VEGF cannot be assessed. Indeed, the responsiveness in CABG-induced increases in EPC and VEGF release is different in patients in the middle tertile (62 to 69 years old). Thus, further experimental studies are necessary to prove that the reduction of VEGF is indeed the limiting factor for circulating EPC levels. Overall, the authors conclude that although administration of EPCs might expand the scope of therapies aimed at promoting neovascularization and tissue regeneration, this may be problematic in elderly patients. This study highlights a potentially relevant feature of the endogenous repair process in elderly patients and poses an interesting question on the value of therapies based on expansion of endogenous EPCs in elderly subjects.
An important question with respect to potential cell therapeutic approaches is whether the endogenous EPC (18) . Other possibilities to augment circulating EPC levels in elderly patients may include the use of statins, which have been shown to increase EPC levels in patients with CAD (19) . One may also consider estrogens (20) or erythropoietin (21) as a possible strategy to increase EPCs. Clearly, the susceptibility to these treatments in elderly patients has not been tested.
Another option may be to more directly influence ageassociated changes in telomere biology ex vivo. Age leads to telomere shortening and dysfunction, which are implicated in senescence and apoptotic signaling. Counteracting the reduction of telomere length by overexpression of the active subunit of the telomerase, TERT, increased the neovascularization capacity of EPCs from healthy volunteers (22) . Likewise, one may consider the use of the telomere repeat binding factor, TRF2, which protects critically short telomeres from fusion and confers protection from oxidative stress in other cell types (23, 24) .
Taken together, although it may still be premature to rush to conclusions about the role of age-related phenomena on EPC-based therapies, the findings reported by Scheubel et al. (15) strengthen the idea that the EPC pool must be stimulated in vivo and most likely expanded ex vivo to enhance neovascularization and improve myocardial function. In light of the results of this study, these approaches would be even more important in elderly individuals.
